524731 — Jenburkt Pharmaceuticals Balance Sheet
0.000.00%
- IN₹4.43bn
- IN₹4.22bn
- IN₹1.52bn
- 76
- 39
- 47
- 57
Annual balance sheet for Jenburkt Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
R2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 561 | 466 | 495 | 740 | 240 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 146 | 179 | 215 | 252 | 211 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 800 | 759 | 811 | 1,097 | 565 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 104 | 113 | 112 | 112 | 547 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 1,212 | 1,429 | 1,418 | 1,651 | 1,962 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 180 | 213 | 158 | 164 | 199 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 227 | 256 | 194 | 202 | 244 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 985 | 1,174 | 1,224 | 1,449 | 1,718 |
| Total Liabilities & Shareholders' Equity | 1,212 | 1,429 | 1,418 | 1,651 | 1,962 |
| Total Common Shares Outstanding |